[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...

ROIV : 31.43 (+0.74%)
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant...

ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)
Roivant's Cash Runway Gets Its Clearest Disclosure in a Year

Barchart Research What to Expect from ROIV Earnings ROIV Generated May 19, 2026 Current Price $28.20 EPS Estimate $$-0.38 Consensus Rating Strong Buy Average Move 5.78% Roivant's Cash Runway Gets Its Clearest...

ROIV : 31.43 (+0.74%)
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq:  IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,...

IMVT : 35.34 (+1.82%)
ROIV : 31.43 (+0.74%)
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday,...

ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved...

ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved...

ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine , underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib...

ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.55 (+2.71%)
ROIV : 31.43 (+0.74%)
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized,...

ABUS : 4.55 (+2.71%)
ROIVW : 2.75 (-3.85%)
ROIV : 31.43 (+0.74%)

Barchart Exclusives

BABA Stock: The Physical AI Race Heats Up as Alibaba Releases New AI Models for Robots
Alibaba is making a bold push into the next frontier of AI, launching new robot-focused models and strengthening its position in the Physical AI market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.